MA27475A1 - Composes de pyrazolo [3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase - Google Patents

Composes de pyrazolo [3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase

Info

Publication number
MA27475A1
MA27475A1 MA28224A MA28224A MA27475A1 MA 27475 A1 MA27475 A1 MA 27475A1 MA 28224 A MA28224 A MA 28224A MA 28224 A MA28224 A MA 28224A MA 27475 A1 MA27475 A1 MA 27475A1
Authority
MA
Morocco
Prior art keywords
sub
sup
optionally substituted
formula
inhibitors
Prior art date
Application number
MA28224A
Other languages
English (en)
Inventor
David George Allen
Diane Mary Coe
Caroline Mary Cook
Michael Dennis Dowle
Christopher David Edlin
Julie Nicole Hamblin
Martin Redpath Johnson
Paul Spencer Jones
Graham Knowles Richard
Jane Mitchell Charlotte
Judith Redgrave Alison
Ward Peter
Kristian Lindvall Mika
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0221455A external-priority patent/GB0221455D0/en
Priority claimed from GBGB0230045.7A external-priority patent/GB0230045D0/en
Priority claimed from GB0306595A external-priority patent/GB0306595D0/en
Priority claimed from GB0308017A external-priority patent/GB0308017D0/en
Priority claimed from GB0319708A external-priority patent/GB0319708D0/en
Priority claimed from GB0321074A external-priority patent/GB0321074D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA27475A1 publication Critical patent/MA27475A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un composé de la formule (I) ou bien un sel de celui-ci, dans laquelle R1 représente alkyle C1-4, fluoroalkyle C1-3, -CH2CH2OH ou -CH2CH2CO2 alkyle C1-2;R2 représente un atome d'hydrogène (H), méthyle ou fluoroalkyle C1;R3 représente cycloalkyle C3-8 facultativement substitué ou cycloalcényle C1-7 facultativement substitué mono-insaturé ou un groupe hétérocyclique facultativement substitué de sous-formule (aa), (bb) ou (cc); dans lesquelles n1 et n2 représentent indépendamment 1 ou 2, et dans lesquelles Y représente O, S, SO2, ou NR10; ou R3 représente un groupe bicyclique (dd) ou (ee); et dans laquelle X représente NR4R5 ou OR5a. Les composés sont des inhibiteurs de phosphodiestérase (PDE), en particulier des inhibiteurs de PDE4. L'invention concerne également l'utilisation d'un composé de la formule (I), ou d'un sel pharmaceutiquement acceptable de celui-ci, dans la fabrication d'un médicament destiné au traitement et/ou à la prophylaxie d'une maladie inflammatoire et/ou allergique chez un mammifère tel que l'homme, par exemple la bronchopneumopathie chronique obstructive (PBCO), l'asthme ou la rhinite allergique.
MA28224A 2002-09-16 2005-04-15 Composes de pyrazolo [3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase MA27475A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0221455A GB0221455D0 (en) 2002-09-16 2002-09-16 Compounds
GBGB0230045.7A GB0230045D0 (en) 2002-12-23 2002-12-23 Compounds
GB0306595A GB0306595D0 (en) 2003-03-21 2003-03-21 Compounds
GB0308017A GB0308017D0 (en) 2003-04-07 2003-04-07 Compounds
GB0319708A GB0319708D0 (en) 2003-08-21 2003-08-21 Compounds
GB0321074A GB0321074D0 (en) 2003-09-09 2003-09-09 Compounds

Publications (1)

Publication Number Publication Date
MA27475A1 true MA27475A1 (fr) 2005-08-01

Family

ID=31999797

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28224A MA27475A1 (fr) 2002-09-16 2005-04-15 Composes de pyrazolo [3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase

Country Status (23)

Country Link
US (2) US20060089375A1 (fr)
EP (1) EP1539753B1 (fr)
JP (1) JP2006503108A (fr)
KR (1) KR20050052501A (fr)
CN (1) CN100387598C (fr)
AT (1) ATE442367T1 (fr)
AU (1) AU2010201417A1 (fr)
BR (1) BR0314392A (fr)
CA (1) CA2497550A1 (fr)
CY (1) CY1109619T1 (fr)
DE (1) DE60329193D1 (fr)
DK (1) DK1539753T3 (fr)
ES (1) ES2331119T3 (fr)
IL (1) IL166898A (fr)
IS (1) IS7709A (fr)
MA (1) MA27475A1 (fr)
MX (1) MXPA05002887A (fr)
NO (1) NO20050841L (fr)
NZ (1) NZ538515A (fr)
PL (1) PL375993A1 (fr)
PT (1) PT1539753E (fr)
SI (1) SI1539753T1 (fr)
WO (1) WO2004024728A2 (fr)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0314392A (pt) * 2002-09-16 2005-07-12 Glaxo Group Ltd Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
WO2004087707A1 (fr) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Composes pyrazolopyrimidines et leur utilisation en medecine
AU2004233827B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
CA2557004A1 (fr) * 2003-12-19 2005-06-30 Glaxo Group Limited Composes pyrazolo [3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de la phosphodiesterase
GB0405933D0 (en) * 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
WO2005090354A1 (fr) * 2004-03-16 2005-09-29 Glaxo Group Limited Composes de pyrazolo[3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de pde4
EP1730104A1 (fr) 2004-04-02 2006-12-13 Glaxo Group Limited Processus chimique et nouvelle forme cristalline
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
ATE415400T1 (de) * 2004-07-05 2008-12-15 Astellas Pharma Inc Pyrazolopyridinderivate
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
JP5281291B2 (ja) 2005-01-10 2013-09-04 グラクソ グループ リミテッド 新規化合物
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US20090131431A1 (en) * 2005-09-29 2009-05-21 Christopher David Edlin Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors
PE20071068A1 (es) 2005-12-20 2007-12-13 Glaxo Group Ltd Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
US7829713B2 (en) * 2006-02-28 2010-11-09 Helicon Therapeutics, Inc. Therapeutic piperazines
US7723330B2 (en) 2006-03-07 2010-05-25 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
EA200801997A1 (ru) 2006-04-20 2009-04-28 Глаксо Груп Лимитед Новые соединения
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
CL2007001829A1 (es) 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
NZ574533A (en) 2006-08-01 2011-05-27 Glaxo Group Ltd Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
WO2009041591A1 (fr) * 2007-09-28 2009-04-02 Kyowa Hakko Kirin Co., Ltd. Dérivé de pyridine fusionnée
EP2070929A1 (fr) * 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Composés d'alkynylaryle et sels correspondants, compositions pharmaceutiques contenant ceux-ci, procédés de préparation de ceux-ci et usage de ceux-ci
AR070564A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Derivados de 1h-pirazolo[3,4-b]piridin-5-ilo,inhibidores de fosfodiesterasas pde4 y antagonistas de receptores muscarinicos de acetilcolina(machr), utiles en el tratamiento y/o profilaxis de enfermedades respiratorias y alergicas,y composiciones farmaceuticas que los comprenden
CL2009000249A1 (es) 2008-02-06 2009-09-11 Glaxo Group Ltd Compuestos derivados de pirazolo[3,4-b] piridin-butanodiamida; composicion farmaceutica; y su uso en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, rinitis, dermatitis atopica, psoriasis.
UY31637A1 (es) * 2008-02-06 2009-08-03 Farmacoforos duales-antagonistas muscarinicos de pde4
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
EP2280946B1 (fr) 2008-06-05 2016-02-10 Glaxo Group Limited Dérivés de 4-carboxamide indazole utiles en tant qu'inhibiteurs de p13 kinases
WO2010094643A1 (fr) 2009-02-17 2010-08-26 Glaxo Group Limited Dérivés de quinoline et applications associées dans la rhinite et l'urticaire
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Ｉｔｋ阻害剤として使用されるピリミジン誘導体
US20120035247A1 (en) 2009-03-19 2012-02-09 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
JP2012520683A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害
AU2010226604A1 (en) 2009-03-19 2011-10-13 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing
WO2010111468A2 (fr) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. INHIBITION PAR INTERFÉRENCE ARN DE L'EXPRESSION DU GÈNE DE LA CHAÎNE BÊTA DU FACTEUR DE CROISSANCE DES NERFS (NGFß) AU MOYEN D'UN ACIDE NUCLÉIQUE INTERFÉRENT COURT (ANSI)
EP2411517A2 (fr) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. Inhibition à médiation par l'interférence arn de l'expression du gène de la molécule d'adhésion intercellulaire 1 (icam-1) faisant appel à de courts acides nucléiques interférents (ansi)
US20120022142A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20120010272A1 (en) 2009-03-27 2012-01-12 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010111490A2 (fr) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. Inhibition à médiation par l'interférence arn de l'expression du gène de la lymphopoïétine stromale thymique (tslp) faisant appel à de courts acides nucléiques interférents (ansi)
US8399436B2 (en) 2009-04-24 2013-03-19 Glaxo Group Limited N-pyrazolyl carboxamides as CRAC channel inhibitors
WO2010122088A1 (fr) 2009-04-24 2010-10-28 Glaxo Group Limited Pyrazole et triazole carboxamides en tant qu'inhibiteurs du canal crac
RS53830B1 (sr) 2009-04-30 2015-06-30 Glaxo Group Limited Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze
WO2011067364A1 (fr) 2009-12-03 2011-06-09 Glaxo Group Limited Nouveaux composés
EP2507231A1 (fr) 2009-12-03 2012-10-10 Glaxo Group Limited Dérivés d'indazole comme inhibiteurs des pi3-kinases
WO2011067365A1 (fr) 2009-12-03 2011-06-09 Glaxo Group Limited Dérivés de benzpyrazole comme inhibiteurs des pi3 kinases
US20120272951A1 (en) 2009-12-16 2012-11-01 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
WO2011110575A1 (fr) 2010-03-11 2011-09-15 Glaxo Group Limited Dérivés de 2-[2-(benzo- ou pyrido-)thiazolylamino]-6- aminopyridine, utiles dans le traitement de maladies respiratoires, allergiques ou inflammatoires
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
WO2011143106A1 (fr) * 2010-05-10 2011-11-17 Gilead Sciences, Inc. Composés pyrazolopyridiniques bifonctionnels
EP2397482A1 (fr) 2010-06-15 2011-12-21 Almirall, S.A. Dérivés d'imidazolone d'hétéroaryle en tant qu'inhibiteurs de JAK
JP2013531687A (ja) 2010-07-16 2013-08-08 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としてのピリジン化合物
EP2613781B1 (fr) 2010-09-08 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Dérivés indazole à utiliser dans le traitement d'une infection par le virus de la grippe
HRP20151017T1 (hr) 2010-09-08 2015-10-23 Glaxosmithkline Intellectual Property Development Limited Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamida
WO2012035055A1 (fr) 2010-09-17 2012-03-22 Glaxo Group Limited Nouveaux composés
JP5795643B2 (ja) 2010-10-21 2015-10-14 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物
WO2012052459A1 (fr) 2010-10-21 2012-04-26 Glaxo Group Limited Composés de pyrazole agissant contre des troubles allergiques, inflammatoires et immunitaires
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
CN102485724B (zh) * 2010-12-06 2015-08-12 中国人民解放军军事医学科学院毒物药物研究所 取代噻吩基吡唑并吡啶类化合物及其医药用途
US20140005188A1 (en) 2011-03-11 2014-01-02 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
EP2527344A1 (fr) 2011-05-25 2012-11-28 Almirall, S.A. Dérivés de pyridin-2(1h)-one utiles comme médicaments pour le traitement de maladies myeloproliferatives, de rejets de greffe, de maladies a médiation immune et de maladies inflammatoires
WO2013136170A1 (fr) 2012-03-16 2013-09-19 Purdue Pharma L.P. Pyridines substituées en tant que bloqueurs des canaux sodiques
EP2935257B1 (fr) 2012-12-20 2018-02-07 Purdue Pharma LP Sulfonamides cycliques en tant que bloquants des canaux sodiques
JP2016525532A (ja) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄異形成症候群の処置
EP3057588A1 (fr) 2013-10-17 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Inhibiteur de pi3k pour le traitement d'une maladie respiratoire
KR20160062179A (ko) 2013-10-17 2016-06-01 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 호흡기 질병의 치료를 위한 ｐｉ３ｋ 억제제
BR112016021641A2 (pt) * 2014-03-27 2017-08-15 Eicosis Llc Potentes inibidores da epóxido hidrolase solúveis
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
WO2015173701A2 (fr) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Compositions pharmaceutiques pour traiter des maladies infecteuses
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
SG11201708793SA (en) 2015-05-12 2017-11-29 Taiho Pharmaceutical Co Ltd Crystals of azabicyclic compound
EP3156405A1 (fr) 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3497100A1 (fr) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Composés chimiques
CN107964011A (zh) * 2016-10-19 2018-04-27 中国人民解放军军事医学科学院毒物药物研究所 取代吡唑并吡啶类衍生物及其医药用途
EP3562828B1 (fr) 2016-12-28 2026-03-18 Dart Neuroscience LLC Composés pyrazolopyrimidinone substitués en tant qu'inhibiteurs de pde2
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
MY202326A (en) 2017-09-14 2024-04-24 Daiichi Sankyo Co Ltd Compound having cyclic structure
US11505559B2 (en) 2017-10-30 2022-11-22 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health Substituted quinoline analogs as aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors
MX2020005447A (es) 2017-11-27 2020-12-03 Dart Neuroscience Llc Compuestos de furanopirimidina sustituida como inhibidores de pde1.
CN111875594A (zh) * 2020-07-21 2020-11-03 中国药科大学 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物
CN116507336B (zh) 2020-09-10 2026-01-02 Vanda制药公司 治疗pde iv介导的疾病或病症的方法
EP4784116A1 (fr) * 2023-09-28 2026-08-05 Merck Sharp & Dohme LLC Dérivés d'azaindazole utiles en tant que modulateurs de hcn2

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US598973A (en) * 1898-02-15 Water-heater and smoke-consumer
US598838A (en) * 1898-02-08 William b
US3856799A (en) * 1971-08-05 1974-12-24 Squibb & Sons Inc Intermediates for production of amino derivatives of pyrazolopyridine carboxylic acids and esters
US3925388A (en) * 1971-08-05 1975-12-09 Squibb & Sons Inc 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters
US3833594A (en) * 1971-08-05 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxylic acids and esters
BE787249A (fr) * 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
US4012373A (en) * 1972-09-22 1977-03-15 E. R. Squibb & Sons, Inc. Pyrazolo[3',4'-2,3]pyrido[4,5-e]b-benzo-1,5-diazepinones
US3840546A (en) * 1972-11-15 1974-10-08 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxamides
US3979399A (en) * 1972-11-15 1976-09-07 E. R. Squibb & Sons, Inc. Amino derivatives of pyrazolopyridine carboxamides
US3833598A (en) * 1972-12-29 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters
US4115394A (en) * 1974-05-06 1978-09-19 E. R. Squibb & Sons, Inc. Amino derivatives of 6-phenylpyrazolo[3,4-b]pyridines
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6326379B1 (en) * 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
US20050043319A1 (en) * 2001-08-14 2005-02-24 Exonhit Therapeutics Sa Molecular target of neurotoxicity
BR0314392A (pt) * 2002-09-16 2005-07-12 Glaxo Group Ltd Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
CA2557004A1 (fr) * 2003-12-19 2005-06-30 Glaxo Group Limited Composes pyrazolo [3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de la phosphodiesterase

Also Published As

Publication number Publication date
CA2497550A1 (fr) 2004-03-25
EP1539753A2 (fr) 2005-06-15
NZ538515A (en) 2007-04-27
IL166898A (en) 2010-06-30
ES2331119T3 (es) 2009-12-22
DK1539753T3 (da) 2010-01-04
DE60329193D1 (de) 2009-10-22
SI1539753T1 (sl) 2009-12-31
AU2010201417A1 (en) 2010-04-29
BR0314392A (pt) 2005-07-12
CN100387598C (zh) 2008-05-14
PL375993A1 (en) 2005-12-12
ATE442367T1 (de) 2009-09-15
WO2004024728A3 (fr) 2004-10-21
KR20050052501A (ko) 2005-06-02
US20080175914A1 (en) 2008-07-24
IS7709A (is) 2005-02-24
AU2003285300A1 (en) 2004-04-30
NO20050841L (no) 2005-06-15
US20060089375A1 (en) 2006-04-27
MXPA05002887A (es) 2005-05-27
PT1539753E (pt) 2009-12-10
WO2004024728A2 (fr) 2004-03-25
CN1694882A (zh) 2005-11-09
JP2006503108A (ja) 2006-01-26
EP1539753B1 (fr) 2009-09-09
CY1109619T1 (el) 2014-08-13

Similar Documents

Publication Publication Date Title
PL375993A1 (en) Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
TW200500364A (en) Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
KR100313641B1 (ko) 6-페닐피리딜-2-아민유도체
NO20063340L (no) Pyrazol-[3,4-B]-pyridinforbindelser, og deres anvendelse som fosfodiesteraseinhibitorer
JP2001510841A (ja) 新規な化合物
JP2014037426A5 (fr)
WO2007040438A3 (fr) Derives d'imidazo(4,5-b) pyridine utilises comme inhibiteurs de la glycogene synthase kinase 3 pour le traitement de la demence et de troubles neurodegeneratifs
CA2749040A1 (fr) Derives de triazolo- et tetrazolopyrimidine en tant qu'inhibiteurs de l'elastase neutrophile humaine (hne) pour le traitement de la maladie pulmonaire obstructive chronique (copd)
KR20180004817A (ko) 삼환형 화합물 및 포스포다이에스터라제 억제제로서 이의 용도
GEP20104973B (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
AU2013358591A1 (en) Pyrimido [4,5-b]quinoline-4,5 (3H,10H)-diones as nonsense mutation suppressors
KR20180128390A (ko) 인돌리논 화합물과 섬유성 질환의 치료에서 이의 용도
WO2007039781A3 (fr) Nouveaux composes
MX2012008147A (es) Derivados de pirrazolopiridina.
ID27509A (id) Turunan piridin tersubstitusi-2,3 proses pembuatannya, komposisi farmasi yang mengandung senyawa tersebut, dan senyawa-antaranya
RU2009109100A (ru) НОВЫЕ 5,7-ДИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ [1,3]ТИАЗОЛО[4,5-d]ПИРИМИДИН-2(3Н)-ОНА И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
WO2016138199A1 (fr) Composés benzothiophène et benzothiazole
CA2837248A1 (fr) Nouveaux derives de phtalazinone -pyrrolopyrimidinecarboxamide
EP1557414A4 (fr) Composes d'isoquinoline et leur utilisation medicinale
RU2012131280A (ru) [4-(5-аминометил-2-фторфенил)пиперидин-1-ил]-(1н-пирролопиридинил)метаноны и их синтез
CA3126689A1 (fr) Compose heteroaryle a noyau fusionne utilise en tant qu'inhibiteur d'alk4/5
MY135776A (en) PYRAZOLO [3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
CN106065018B (zh) 取代的吲哚化合物及其使用方法和用途
EP2470531A1 (fr) Méthylpyrrolopyrimidine-carboxamides
RU2021103602A (ru) Производные тирозинамида в качестве ингибиторов rho-киназы